NIFEDIPINE CAPSULE

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Compra

Scheda tecnica Scheda tecnica (SPC)
01-12-2023

Principio attivo:

NIFEDIPINE

Commercializzato da:

AA PHARMA INC

Codice ATC:

C08CA05

INN (Nome Internazionale):

NIFEDIPINE

Dosaggio:

5MG

Forma farmaceutica:

CAPSULE

Composizione:

NIFEDIPINE 5MG

Via di somministrazione:

ORAL

Confezione:

100

Tipo di ricetta:

Prescription

Area terapeutica:

DIHYDROPYRIDINES

Dettagli prodotto:

Active ingredient group (AIG) number: 0115253003; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2010-06-14

Scheda tecnica

                                _NIFEDIPINE (Nifedipine Capsules) _
_Page 1 of 36_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
NIFEDIPINE
Nifedipine Capsules
Capsules, 5 mg and 10 mg, Oral
USP
Anti-Anginal Agent
AA PHARMA INC.
1165 Creditstone Road Unit # 1
Vaughan, Ontario
L4K 4N7
www.aapharma.ca/en/
Date of Initial Authorization:
JUN 16, 2010
Date of Revision:
DEC 01, 2023
Submission Control Number: 271662
_NIFEDIPINE (Nifedipine Capsules) _
_Page 2 of 36_
RECENT MAJOR LABEL CHANGES
None
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
...................................................................................................................
4
1.1
Pediatrics
.................................................................................................................
4
1.2
Geriatrics
.................................................................................................................
4
2
CONTRAINDICATIONS
.......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
......................................................................................
5
4.1
Dosing Considerations
.............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
........................................................ 5
4.4
Administration
.........................................................................................................
5
4.5
Missed Dose
...............................................................................
                                
                                Leggi il documento completo
                                
                            

Documenti in altre lingue

Scheda tecnica Scheda tecnica francese 01-12-2023

Cerca alert relativi a questo prodotto

Visualizza cronologia documenti